Orlifit 60mg Capsule
Orlifit 60mg Capsule (Orlistat) is the first drug in a new class of nonsystemically acting anti-obesity drugs known as lipase inhibitors. Chemically Orlifit 60mg Capsule is (S)-2-formylamino-4-methyl-pentanoic acid (S)-1-[[(2S, 3S)-3-hexyl-4-oxo-2-oxetanyl] methyl]- dodecyl ester. Orlifit 60mg Capsule molecular formula is C29H53NO5 . Orlifit 60mg Capsule is used in combination with diet adjustment in obese patients to manage their weight
Organic causes of obesity, such as hypothyroidism, should be excluded before prescribing orlistat. – Orlistat should be stopped after 3 months if the patient has not lost 5% of body weight and stopped at 6 months if the patient has not lost 10% of body weight. – The daily intake of fat should be distributed over three main meals. If orlistat is taken with any one meal very high in fat, the possibility of gastrointestinal effects may increase. – Weight loss induced by orlistat accompanied by improved metabolic control in type 2 diabetics might require reduction in the dose of hypoglycemic medication (e.g., sulfonylureas). Cyclosporine A decrease in cyclosporine plasma levels has been observed, when orlistat was administered concomitantly. Therefore the combination is not recommended. However, if such concomitant use is unavoidable, to reduce the chance of drug-drug interaction cyclosporine should be taken 2 hours after or before orlistat. In addition more frequent monitoring of cyclosporine blood levels should be performed both after addition of orlistat and upon discontinuation of orlistat in cyclosporine treated patients.
Orlifit 60mg Capsule is used in combination with diet adjustment in obese patients to manage their weight
Patients administered with this medication may experience headache, dizziness, throat irritation, cough, dry mouth, and nausea. Patients may also experience constipation, urinary retention (inability to urinate completely), occasional paradoxical bronchospasm (narrowing or spasm of airway), tachycardia (increased heart rate), and arrhythmias (disorder of heart rhythm)
When not use
This medication is contraindicated in case of hypersensitivity to the active substance i.e. ipratropium bromide or to atropine.